Questions across 4 calls

Anirudh Shetty

Solidarity Advisors Private Limited

Neuland Laboratories Limited

Neuland Laboratories Limited CC-Mar24.pdf · 2024-05-14

Hi, thanks for the opportunity. I had two questions. So , you, skip out the China plus one opportunity for a lot of questions. I just wondered some of your thoughts on, there would be manufacturing of API of, the CSM in the West as well in Europe. So, with all the cost challenges that are happening there, or, so me of them might have abated but are you also seeing a lot of opportunity come your way because of an unwillingness to invest further, so more of a, West plus one, Europe plus one. So just wanted your thoughts around that.

No, it answers my question. Just one follow -up here. Are you, basis your track record of good quality. Are you seeing customers looking at your differently? Because now the respect for capabilities has gone up. So, the willingness to start comparing your products with a player in Europe is now something that they're considering more seriously today than, what say they would have in the past. Are you seeing that change in customer? Are you seeing that customers might be looking at your differently today?

Neuland Laboratories Limited CC-Dec23.pdf · 2024-02-09

Just one question. You have given an indication of how your revenues, evolving over a 3-to-4- year time horizon. But given our focus is early on more profitable growth, then shouldn't we really be looking more at what how profits can grow over the next 3 to 4 years? And is my understanding right that the profit growth can actually be faster than the custom synthesis business where we have a very strong pipeline and growing faster can grow as a share of revenue and this is higher margin. And we could also see some operating leverage on our Unit 3, which is at 57% right now. So how do you guys think about if you are able to grow at 20% revenue? How does one think about profit growth in purchase scenario?

No, very helpful. But I just wanted to clarify your point on the margins in specialty and CMS being similar. I presume at an EBITDA level you meant. And but what would explain why it's a similar margin because it seems a bit counter intuitive. And I though t that the CMS is a more profitable segment for us because it's a patented product and the customer wants more supply in security, trust in IP, and they're willing to give it better pricing is also more amenable in that segment?

SBI Life Insurance Company Limited

SBI Life Insurance Company Limited CC-Mar24.pdf · 2024-04-26

Thanks for the opportunity. So my first question is around the GTI business. You shared the APE figure for FY '24, could you share that for the FY '23 as well?

Got it. And sir, this business while we're calculating our VNB for this, do we assume it to be a yearly sort of business o r do we also make an assumption that the business could get renewed and so we kind of take it on a more multiyear type of recognition?

HDFC Life Insurance Company Limited

HDFC Life Insurance Company Limited CC-Dec23.pdf · 2024-01-12

My first question is essentially on the draft document around surrender charges. I know it's at early stages of discussion and there is a range of outcomes that can happen, but assuming a more extreme outcome happening in terms of the capping of charges. How does one think about implications for us? And could you talk a little bit more about our non-par product in terms of what would the persistency that we kind of see in this product and how much of the margin could get impacted, we see a more extreme capping of charges in in this product segment?

My next question is our non-par product is fairly unique in terms of ability to give our customers the ability to lock in and earn a certain yield for a long period of time. Do y ou see this unique value proposition getting diluted if say you know customers could buy long term G-Secs directly on a trading platform?